Suppr超能文献

相似文献

1
2
Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis.
Blood Cancer J. 2020 Feb 25;10(2):21. doi: 10.1038/s41408-020-0289-2.
4
Impact of JAK2V617F Mutational Status on Phenotypic Features in Essential Thrombocythemia and Primary Myelofibrosis.
Turk J Haematol. 2016 Jun 5;33(2):94-101. doi: 10.4274/tjh.2014.0136. Epub 2015 Apr 27.
7
[Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Orv Hetil. 2011 Nov 6;152(45):1795-803. doi: 10.1556/OH.2011.29226.
8
[Splanchnic vein thrombosis as a first manifestation of Primary myelofibrosis].
Gac Med Mex. 2017;153(4):537-540. doi: 10.24875/GMM.17002822.
9
Thrombosis in primary myelofibrosis: incidence and risk factors.
Blood. 2010 Jan 28;115(4):778-82. doi: 10.1182/blood-2009-08-238956. Epub 2009 Nov 20.
10
Thromboses and hemorrhages are common in MPN patients with high JAK2V617F allele burden.
Ann Hematol. 2017 Aug;96(8):1297-1302. doi: 10.1007/s00277-017-3040-8. Epub 2017 Jun 6.

引用本文的文献

2
Multiple Aneurysms and Thrombotic Events as Initial Manifestations of Primary Myelofibrosis: A Case Report.
Cureus. 2025 Feb 23;17(2):e79519. doi: 10.7759/cureus.79519. eCollection 2025 Feb.
3
Thrombosis, major bleeding, and mortality in 1079 patients with myelofibrosis: a matched population-based study.
Blood Adv. 2025 Jun 10;9(11):2783-2793. doi: 10.1182/bloodadvances.2025016247.
4
Impact of somatic gene mutations on the risk of thrombosis in myelofibrosis.
Leukemia. 2024 Nov;38(11):2483-2486. doi: 10.1038/s41375-024-02389-2. Epub 2024 Aug 30.
5
Pediatric Philadelphia-Negative Myeloproliferative Neoplasms in the Era of WHO Classification: A Systematic Review.
Diagnostics (Basel). 2023 Jan 19;13(3):377. doi: 10.3390/diagnostics13030377.
8
Multi-focal Lytic Lesions in a Patient with Myelofibrosis: A Case Report.
Cureus. 2020 Mar 30;12(3):e7475. doi: 10.7759/cureus.7475.
10
Azygos continuation of the caudal vena cava with segmental aneurysm, lung lobe torsion and pulmonary thromboembolism in a dog.
Clin Case Rep. 2018 Jan 4;6(2):363-369. doi: 10.1002/ccr3.1365. eCollection 2018 Feb.

本文引用的文献

1
Thrombosis in primary myelofibrosis: incidence and risk factors.
Blood. 2010 Jan 28;115(4):778-82. doi: 10.1182/blood-2009-08-238956. Epub 2009 Nov 20.
2
Cancer, clots and consensus: new understanding of an old problem.
J Clin Oncol. 2009 Oct 10;27(29):4821-6. doi: 10.1200/JCO.2009.22.3032. Epub 2009 Sep 14.
3
Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action.
J Clin Oncol. 2009 Oct 10;27(29):4919-26. doi: 10.1200/JCO.2009.22.3214. Epub 2009 Aug 31.
4
Prevention of venous thromboembolism in hospitalized patients with cancer.
J Clin Oncol. 2009 Oct 10;27(29):4874-80. doi: 10.1200/JCO.2009.22.3644. Epub 2009 Aug 24.
6
Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation.
Leukemia. 2008 Nov;22(11):2020-8. doi: 10.1038/leu.2008.253. Epub 2008 Sep 18.
7
Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera.
Blood. 2008 Nov 15;112(10):4061-8. doi: 10.1182/blood-2008-06-164087. Epub 2008 Sep 3.
10
Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey.
Blood. 2008 Jan 15;111(2):666-71. doi: 10.1182/blood-2007-07-102665. Epub 2007 Oct 1.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验